Related Experiment Video
Updated: Jun 26, 2026

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair
Published on: October 16, 2021
Revascularization for Coronary Artery Disease and Mitral Regurgitation: A Systematic Review and Meta-analysis
Ryaan El-Andari1, Ashlyn Kruggel1, Mitchell Wagner2
1From the Division of Cardiac Surgery, Department of Surgery, University of Alberta, Edmonton, AB.
Insights
Coronary artery bypass grafting (CABG) is associated with lower long-term mortality and heart failure hospitalizations compared to percutaneous coronary intervention (PCI) in patients with multivessel coronary artery disease and ischemic mitral regurgitation. CABG is recommended for eligible patients.
Area of Science:
- Cardiology
- Interventional Cardiology
- Cardiac Surgery
Background:
- Coronary artery disease (CAD) and ischemic mitral regurgitation (IMR) frequently coexist.
- Optimal treatment strategies for patients with both conditions remain unclear.
Purpose of the Study:
- To compare the outcomes of coronary artery bypass grafting (CABG) versus percutaneous coronary intervention (PCI) in patients with multivessel CAD and IMR.
- To evaluate long-term mortality, myocardial infarction, stroke, heart failure hospitalizations, and mitral regurgitation recurrence.
Main Methods:
- Systematic review and meta-analysis of studies comparing CABG and PCI for multivessel CAD with IMR.
- Searched PubMed and Embase databases.
- Included 8 studies after full-text review of 1285 identified articles.
Main Results:
- Initial pooled analysis showed no significant difference in long-term mortality, with considerable heterogeneity.
- Exclusion of an outlier improved heterogeneity, favoring CABG over PCI for mortality (OR: 1.39, 95% CI: 1.06-1.83).
- Rehospitalization for heart failure also significantly favored CABG (OR: 1.49, 95% CI: 1.16-1.92).
Conclusions:
- CABG demonstrated lower rates of long-term mortality and heart failure hospitalizations compared to PCI.
- CABG is the preferred revascularization strategy for patients with multivessel CAD and IMR who have acceptable surgical risk.
Background:
Coronary artery disease (CAD) and ischemic mitral regurgitation (IMR) commonly co-exist, yet the optimal intervention for these patients is unclear. Herein, we perform a systematic review and meta-analysis comparing the outcomes of patients with multivessel CAD and IMR undergoing coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI).
Methods:
PubMed and Embase were systematically searched for articles comparing outcomes of patients with CAD and IMR undergoing revascularization with CABG or PCI, with or without concomitant mitral valve interventions. Thousand two hundred eighty-five studies were identified and 8 were included in this review after full text review. The primary outcome of this study was mortality, and secondary outcomes included myocardial infarction, stroke, heart failure hospitalizations, and residual or recurrent mitral regurgitation.
Results:
Pooled analyses identified no significant differences in long-term mortality [odds ratio (OR): 1.13, 95% confidence interval (CI): 0.77-1.68, P = 0.53] with considerable heterogeneity between studies. However, following the exclusion of a single outlier, heterogeneity in the pooled analysis of long-term mortality improved and the outcome favored CABG over PCI (OR: 1.39, 95% CI: 1.06-1.83, P = 0.02). Rehospitalization for heart failure also favored CABG (OR: 1.49, 95% CI: 1.16-1.92, P = 0.002).
Conclusion:
This systematic review and meta-analysis suggested lower rates of long-term mortality and heart failure hospitalizations for CABG compared to PCI. CABG remains preferrable for patients with acceptable surgical risk, multivessel CAD, and IMR.
More Related Videos
Related Concept Videos
Mitral Regurgitation III: Medical Management
Mitral Regurgitation IV: Nursing Management
Mitral Regurgitation II: Clinical Features and Diagnostic Tests
Mitral Regurgitation I: Introduction
Mitral Stenosis III: Medical Management
Aortic Regurgitation III: Medical Management

